Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

A trial pitting weight loss jab Mounjaro against competitor Wegovy ended with one clear winner, and Mounjaro is getting ...

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...

Weight loss drugs, including Wegovy (semaglutide) and Mounjaro (tirzepatide), are becoming increasingly popular among those ...

The side effects of taking Mounjaro can be very varied, and the drug tends to affect people differently. The most common side effects include feeling sick, diarrhoea, constipation, vomiting, heartburn ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

It's estimated that around 1.5 million Brits are now taking weight-loss drugs, such as Wegovy, Ozempic, Mounjaro, Saxenda and Orlistat.

Hair loss is becoming a concern for some individuals using weight loss medications such as Ozempic, Wegovy and Zepbound — popular drugs that offer rapid weight loss ...

At the same time, and likely because of this, data shows that demand for bariatric surgery has plunged, dropping nearly 26 ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next ...

Hims and Hers stock rally looms with bullish EMAs, Novo Nordisk partnership, ZAVA acquisition, and new product launches ...